Previous Close | 31.95 |
Open | 32.04 |
Bid | 26.08 x 3200 |
Ask | 34.00 x 1200 |
Day's Range | 31.58 - 33.76 |
52 Week Range | 21.65 - 40.69 |
Volume | |
Avg. Volume | 1,531,629 |
Market Cap | 2.135B |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.86 |
Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 59.68 |
Subscribe to Yahoo Finance Plus to view Fair Value for GBT
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the trial
Global Blood Therapeutics' (NASDAQ: GBT) stock rose by more than 8.2% on Wednesday as of 2:40 p.m. ET on news that the company initiated a phase 2/3 clinical trial for its candidate called GBT601, which is being developed to treat sickle cell disease. The trial will be the biotech's fourth ongoing late-stage sickle cell disease therapy project, not to mention a trio of earlier-stage projects for the same indication. Global Blood Therapeutics already has one medicine approved to treat sickle cell disease called Voxelotor.
Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trialSOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor. The study (NCT05431088) is a randomized, multicenter Phase 2/3 clinical trial evaluat